Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Protein subunit |
Clinical data | |
Routes of administration | Intramuscular |
Identifiers | |
DrugBank |
Part of a series on the |
COVID-19 pandemic |
---|
|
COVID-19 portal |
West China Hospital COVID-19 vaccine is a COVID-19 vaccine candidate developed by Jiangsu Province Centers for Disease Control and Prevention, West China Hospital and Sichuan University.[citation needed]
In August 2020, WestVac Biopharma started phase I clinical trials with 168 participants in China.[1]
In November, WestVac Biopharma started phase II clinical trials with 960 participants in China[2] In February 2021, WestVac Biopharma started phase IIb clinical trials with 4,000 participants in China. Later, WestVac Biopharma is no longer on phase IIb clinical trial.[3]
In June 2021, WestVac Biopharma started phase III trials with 40,000 participants including Indonesia, Kenya, and the Philippines.[4]
In August 2021 WestVac Biopharma started phase I/II trials with 600 participants for children and adolescents aged 6-17.[5]
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|